Irvin Gastman, DO
Public Health & General Preventive Medicine · Detroit, MINPI 1942263843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,160 and has fallen 72.3% since, to $599 in 2025.
Across 442 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$744
- Esperion Therapeutics, Inc.$661
- AstraZeneca$641
- Pfizer$623
- plus $4K from 20 others
What the payments were for
- Speaking & faculty fees$1111%
- Food & beverage$9,02699%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 94 | $1,458 |
| Lilly USA, LLC | 69 | $1,324 |
| Boehringer Ingelheim | 31 | $744 |
| Esperion Therapeutics, Inc. | 23 | $661 |
| AstraZeneca | 39 | $641 |
| Pfizer | 35 | $623 |
| Amgen | 14 | $510 |
| Novartis | 25 | $502 |
| Bayer | 18 | $437 |
| AbbVie(2 entities) | 20 | $432 |
| Sumitomo Pharma America, Inc. | 9 | $364 |
| Johnson & Johnson | 20 | $359 |
| Otsuka America Pharmaceutical, Inc. | 4 | $281 |
| Lexicon Pharmaceuticals, Inc. | 8 | $162 |
| Bioventus LLC | 6 | $140 |
| Novo Nordisk | 6 | $126 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Eisai Inc. | 3 | $53 |
| Merck | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Orthogenrx Inc. | 1 | $28 |
| Exact Sciences | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few public health & general preventive medicine providers in Michiganto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $119,190 |
| JardianceEmpagliflozin | 101 | $110,272 |
| MounjaroTirzepatide | 22 | $45,536 |
| KerendiaFinerenone | 23 | $35,497 |
| OzempicSemaglutide | 20 | $29,826 |
| XareltoRivaroxaban | 23 | $29,803 |
| EliquisApixaban | 20 | $28,879 |
| TrulicityDulaglutide | 23 | $26,972 |
| GemtesaVibegron | 19 | $21,777 |
| MultaqDronedarone Hcl | 16 | $21,034 |
| EntrestoSacubitril/Valsartan | 17 | $20,611 |
| FarxigaDapagliflozin Propanediol | 11 | $15,107 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $8,620 |
| Chlorthalidone | 155 | $2,910 |
| Atorvastatin Calcium | 195 | $2,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,458 | $119,190110 claims |
| Boehringer IngelheimJardiance | $744 | $110,272101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,324 | $72,50845 claims |
| BayerKerendia | $437 | $35,49723 claims |
| Novo NordiskOzempic | $126 | $29,82620 claims |
| Johnson & JohnsonXarelto | $359 | $29,80323 claims |
| PfizerEliquis | $623 | $28,87920 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $364 | $21,77719 claims |
| NovartisEntresto | $502 | $20,61117 claims |
| AstraZenecaFarxiga | $641 | $15,10711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few public health & general preventive medicine providers in Michiganon file to place this against a meaningful peer group, so we don't.
Other public health & general preventive medicine in Detroit
- Mohammad SheikhDetroit$138
- Elie KhouryDetroit$114
- Edward RosickEast Lansing$79K
- Trissa TorresGrand Blanc$56K
- Janet GreenhutAnn Arbor$10K
- Diana Torres-BurgosYpsilanti$3K
- David ShareYpsilanti$357
- David PawsatEast Lansing$271
- Mohamad HamdiRochester Hills$126
- Richard TookerAllegan$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.